25
Participants
Start Date
January 31, 2008
Primary Completion Date
May 31, 2012
Study Completion Date
May 31, 2012
AGS-003
Dendritic cell Immunotherapeutic
Sunitinib
An approved drug for the treatment of RCC
Urology of Virginia-Sentara Medical Group, Norfolk
Carolina's Medical Center / Blumenthal Cancer Center, Charlotte
Emory University, Atlanta
Barrett Cancer, Cincinnati
The Indiana University Cancer Center, Indianapolis
University of Iowa, Iowa City
University of Minnesota Cancer Center, Minneapolis
University of Kansas Hospital, Kansas City
CORTPA, Dallas
The Urology Center of Colorado, Denver
UCLA, Los Angeles
City of Hope, Duarte
Princess Margaret Hospital, Toronto
Jewish General Hospital, Montreal
Lead Sponsor
Argos Therapeutics
INDUSTRY